Long-Segment SFA Stenting—The Dark Sides: In-Stent Restenosis,Clinical Deterioration,and Stent Fractures

Abstract

Purpose:

To determine and compare the rates of in-stent restenosis, late clinical deterioration, and stent fractures in nitinol stents versus Wallstents implanted for suboptimal angioplasty in the superficial femoral artery (SFA).

Methods:

Interrogation of an angioplasty database identified 286 consecutive patients (178 men; mean age 67±10 years, range 44–87) with severe claudication (n=254) or critical limb ischemia (n=32) who had stents implanted after suboptimal angioplasty over a 5-year period. Wallstents with a mean stented lesion length of 107±71 mm were implanted in 116 patients, while nitinol stents were used in 170 patients: 45 SMART stents (mean stented lesion length 139±88 mm) and 125 Dynalink/Absolute stents (mean stented lesion length 125±84 mm). Patients were followed for in-stent restenosis (>50%) by duplex ultrasound, clinical deterioration by at least 1 Fontaine stage compared to baseline, and stent fractures by biplanar radiography.

Results:

In-stent restenosis rates at 1, 2, and 3 years were 46%, 66%, and 72% for Wallstents compared to 20%, 36%, and 53% for nitinol stents (p < 0.001), respectively, without significant difference between the 2 nitinol stent groups (p=0.59). Clinical deterioration at 1, 2, and 3 years was found in 10%, 15%, and 18% with Wallstents versus 4%, 5%, and 5% with nitinol stents (p=0.014), respectively, without difference between the 2 nitinol stent groups (p=0.47). Fracture rates were 19% for Wallstents after a mean 43±24 months, 28% for SMART stents after mean 32±16 months, and 2% for Dynalink/Absolute stents after a mean 15±9 months.

Conclusions:

Intermediate-term in-stent restenosis remains a major problem even with current nitinol stent technology; however, clinical deterioration seems no matter of serious concern with SMART and Dynalink/Absolute stents. Stent fractures may be lower with Dynalink/Absolute stents, but randomized head-to-head comparisons are needed to validate these data.

Keywords

peripheral artery disease superficial femoral artery stents nitinol stent restenosis stent fracture

Get full access to this article

View all access options for this article.

References

Dormandy

Rutherford

. Management of peripheral arterial disease (PAD) TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg. 2000; 31: S1–S296.

Johnston

. Femoral and popliteal arteries: Reanalysis of results of balloon angioplasty. Radiology. 1992; 183: 767–771.

Minar

Pokrajac

Maca

. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: Results of a prospective randomized study. Circulation. 2000; 102: 2694–2699.

Capek

McLean

Berkowitz

. Femoropopliteal angioplasty. Factors influencing long-term success. Circulation. 1991; 83: I70–80.

Cejna

Turnher

Illiasch

. PTA versus Palmaz stent in femoropopliteal artery obstructions: A multicenter prospective randomized study. J Vasc Interv Radiol. 2001; 12: 23–31.

Vroegineweij

Vos

Tielbeek

. Balloon angioplasty combined with primary stenting versus balloon angioplasty alone in femoropopliteal obstructions: A comparative randomized study. Cardiovasc Intervent Radiol. 1997; 20: 420–425.

Grimm

Muller-Hulsbeck

Jahnke

. Randomized study to compare PTA with Palmaz stent placement for femoropopliteal lesions. J Vasc Interv Radiol. 2001; 12: 935–942.

Zdanowski

Albrechtsson

Lundin

. Percutaneous transluminal angioplasty with or without stenting for femoropopliteal occlusions? A randomized controlled study. Int Angiol. 1999; 18: 251–255.

Becquemin

Favre

Marzelle

. Systematic vs. selective stent placement after superficial femoral artery balloon angioplasty: A multicenter prospective randomized study. J Vasc Surg. 2003; 37: 487–494.

10.

Duda

Pusich

Richter

. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: Six-month results. Circulation. 2002; 106: 1505–1509.

11.

Sabeti

Amighi

Ahmadi

. Outcome of long-segment femoropopliteal stent implantation using self-expanding nitinol stents. J Endovasc Ther. 2005; 12: 6–12.

12.

Lugmayr

Holzer

Kastner

. Treatment of complex arteriosclerotic lesions with nitinol stents in the superficial femoral and popliteal arteries: A midterm follow-up. Radiology. 2002; 222: 37–43.

13.

Sabeti

Schillinger

Amighi

. Patency of nitinol vs. Wallstents in the superficial femoral artery—a propensity score adjusted analysis. Radiology. 2004; 232: 516–521.

14.

Duda

Bosiers

Lammer

. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: The SIROCCO II trial. J Vasc Interv Radiol. 2005; 16: 331–338.

15.

Scheinert

Sax

. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol. 2005; 45: 312–315.

16.

Ranke

Creutzig

Alexander

. Duplex scanning of the peripheral arteries: Correlation of the peak velocity ratio with angiographic diameter reduction. Ultrasound Med Biol. 1992; 18: 433–440.